The CAV1 Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population engineered from the human 786-O clear cell renal cell carcinoma line, harboring a targeted disruption of the caveolin-1 (CAV1) gene. This loss-of-function model avoids clonal selection and retains population-level heterogeneity, making it suitable for studying the consequences of CAV1 deficiency in a genetically relevant kidney cancer background. The product enables detailed examination of caveolin-1??s contributions to signal transduction, membrane trafficking, and tumor cell behavior.
The parental 786-O cell line is a widely used model for clear cell renal cell carcinoma (ccRCC), characterized by a mutant VHL gene that leads to constitutive stabilization of hypoxia-inducible factors (HIFs) and a pseudo-hypoxic state. This line is extensively applied in investigations of tumorigenesis, metastasis, and therapeutic response, reflecting key molecular features of sporadic ccRCC. The VHL-null background creates a permissive environment for interrogating the interplay between caveolin-1 function and oncogenic signaling networks.
Caveolin-1 is a multifunctional scaffolding protein and the principal component of caveolae, plasma membrane microdomains that orchestrate endocytosis, cholesterol trafficking, and signal transduction. CAV1 directly binds and inhibits a panel of signaling proteins, including Src family kinases, H-Ras, and endothelial nitric oxide synthase (eNOS), maintaining them in an inactive state within caveolar invaginations. Its regulation involves upstream factors such as transforming growth factor-beta (TGF-??), epidermal growth factor (EGF), Src kinase, and cholesterol; downstream effectors include EGFR, TGF-?? receptor, ??-catenin, and components of the MAPK/ERK (Ras-Raf-MEK-ERK1/2), PI3K/AKT, and JAK/STAT pathways. Additionally, CAV1 interacts with integrin ??1 and filamin to modulate adhesion and mechanotransduction, positioning it at the nexus of growth factor, integrin, and cytokine signaling.
Within the 786-O ccRCC system, CAV1 knockout provides a powerful tool for dissecting caveolin-1??s contextual roles, which range from tumor suppression to oncogenic facilitation in kidney cancer. Disruption of its inhibitory scaffolding is predicted to release constraints on multiple proliferative and migratory pathways, potentially synergizing with HIF-driven transcriptional programs to enhance invasive and metabolic phenotypes. This model allows researchers to investigate how loss of caveolae-mediated signal compartmentalization collaborates with VHL deficiency to promote ccRCC progression.
This CAV1 knockout polyclonal cell population is compatible with a broad range of functional and molecular assays, including Western blotting, RT-qPCR, immunofluorescence, cell migration and invasion assays, proliferation measurements (MTT/BrdU), phospho-protein analysis, co-immunoprecipitation, and flow cytometry. The model is particularly suited for studies in renal cell carcinoma biology, signal transduction modulation, drug resistance, and cancer metabolism. For additional information, please contact Ascent Research.
